338 related articles for article (PubMed ID: 9771846)
1. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action.
Jordan SC; Quartel AW; Czer LS; Admon D; Chen G; Fishbein MC; Schwieger J; Steiner RW; Davis C; Tyan DB
Transplantation; 1998 Sep; 66(6):800-5. PubMed ID: 9771846
[TBL] [Abstract][Full Text] [Related]
2. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
[TBL] [Abstract][Full Text] [Related]
3. Effect of anti-HLA antibodies on the long-term survival of heart and kidney allografts.
Barr ML; Cohen DJ; Benvenisty AI; Hardy M; Reemtsma K; Rose EA; Marboe CC; D'Agati V; Suciu-Foca N; Reed E
Transplant Proc; 1993 Feb; 25(1 Pt 1):262-4. PubMed ID: 8438294
[TBL] [Abstract][Full Text] [Related]
4. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
6. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss.
Panigrahi A; Gupta N; Siddiqui JA; Margoob A; Bhowmik D; Guleria S; Mehra NK
Hum Immunol; 2007 May; 68(5):362-7. PubMed ID: 17462503
[TBL] [Abstract][Full Text] [Related]
7. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies.
Akalin E; Dinavahi R; Friedlander R; Ames S; de Boccardo G; Sehgal V; Schröppel B; Bhaskaran M; Lerner S; Fotino M; Murphy B; Bromberg JS
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1160-7. PubMed ID: 18337549
[TBL] [Abstract][Full Text] [Related]
8. Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation.
Matinlauri IH; Kyllönen LE; Eklund BH; Koskimies SA; Salmela KT
Transplantation; 2004 Jul; 78(2):198-204. PubMed ID: 15280678
[TBL] [Abstract][Full Text] [Related]
9. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice.
Wasowska BA; Qian Z; Cangello DL; Behrens E; Van Tran K; Layton J; Sanfilippo F; Baldwin WM
Transplantation; 2001 Mar; 71(6):727-36. PubMed ID: 11330533
[TBL] [Abstract][Full Text] [Related]
10. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
11. [Role of antibodies in kidney transplant].
Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
[TBL] [Abstract][Full Text] [Related]
12. Specificity and Ig class of preformed alloantibodies causing a positive crossmatch in renal transplantation. The implications for graft survival.
ten Hoor GM; Coopmans M; Allebes WA
Transplantation; 1993 Aug; 56(2):298-304. PubMed ID: 7689256
[TBL] [Abstract][Full Text] [Related]
13. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
Aubert V; Venetz JP; Pantaleo G; Pascual M
Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474
[TBL] [Abstract][Full Text] [Related]
14. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients.
Glotz D; Haymann JP; Sansonetti N; Francois A; Menoyo-Calonge V; Bariety J; Druet P
Transplantation; 1993 Aug; 56(2):335-7. PubMed ID: 8356587
[TBL] [Abstract][Full Text] [Related]
15. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
[TBL] [Abstract][Full Text] [Related]
16. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ.
Tyan DB; Li VA; Czer L; Trento A; Jordan SC
Transplantation; 1994 Feb; 57(4):553-62. PubMed ID: 8116041
[TBL] [Abstract][Full Text] [Related]
18. Antibody-mediated rejection: treatment alternatives and outcomes.
Singh N; Pirsch J; Samaniego M
Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
[TBL] [Abstract][Full Text] [Related]
19. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients.
Banasik M; Boratyńska M; Nowakowska B; Haloń A; Kościelska-Kasprzak K; Drulis-Fajdasz D; Patrzałek D; Weyde W; Klinger M
Transplant Proc; 2007 Nov; 39(9):2718-20. PubMed ID: 18021967
[TBL] [Abstract][Full Text] [Related]
20. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
